Inimex and SARomics Announce Achievement of Scientific Milestone in Structural Biology Collaboration

15-Dec-2010 - Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex’s Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were ...

Inimex Announces Appointment of New CEO

25-Nov-2009 - Inimex Pharmaceuticals, Inc. announced that it has appointed Michael J. Abrams, Ph.D as its President and CEO. Abrams brings more than 25 years of drug discovery and development experience to Inimex. He is a co-inventor of the nuclear medicine imaging agent, Cardiolite, and worked from 1984 to ...

Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator

Phase 1 healthy volunteer study of IMX942 will provide human safety and pharmacodynamic data

30-Apr-2009 - Inimex Pharmaceuticals announced that its novel Innate Defense Regulator (IDR) IMX942 was administered to human subjects for the first time on April 27, 2009. The healthy volunteers were enrolled in a Phase 1 safety study of IMX942 being performed for Inimex in Montreal with the approval of ...

Inimex Raises US $22 Million in the Fight Against Antibiotic Resistance

06-Jun-2008 - Inimex Pharmaceuticals, Inc. announced the closing of a US $22 Million Series B venture financing. Leading the round was Morningside Venture Investments Ltd., joined by additional new investors Roche Venture Fund, Switzerland, CA-based Astellas Venture Management LLC, the corporate venture ...